Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: Current issues and new agents

Lynne Strasfeld, David M. Weinstock

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Invasive candidiasis and invasive mold infections cause significant morbidity and mortality in the hematopoietic stem cell transplant population, in particular in recipients of allografts. The introduction of a variety of new antifungal compounds over the past decade has focused attention on prophylactic strategies as a means to decrease the burden of invasive fungal infections (IFIs). Until recently, fluconazole has been the standard agent for prophylaxis before and after engraftment. In 2005, the echinocandin micafungin received US FDA approval for prophylaxis against IFIs in stem cell transplant recipients during the neutropenic period prior to engraftment. In patients with substantial risk for invasive mold infection, many centers now use a mold-active antifungal agent (e.g., a triazole such as itraconazole, voriconazole or posaconazole, or an echinocandin) as prophylaxis after engraftment. Several recent studies have highlighted the efficacy of these newer agents in preventing IFIs in these highly immunocompromised patients. This review will discuss current issues in IFI and new agents available for prophylaxis in allogeneic hematopoietic stem cell transplant recipients.

Original languageEnglish (US)
Pages (from-to)457-468
Number of pages12
JournalExpert Review of Anti-Infective Therapy
Volume4
Issue number3
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Hematopoietic Stem Cells
Echinocandins
Transplants
Fungi
Invasive Candidiasis
Triazoles
Itraconazole
Fluconazole
Antifungal Agents
Immunocompromised Host
Infection
Allografts
Stem Cells
Morbidity
Mortality
Invasive Fungal Infections
Transplant Recipients
Population

Keywords

  • Antifungals
  • Prophylaxis
  • Stem cell transplant
  • Voriconazole

ASJC Scopus subject areas

  • Infectious Diseases
  • Parasitology

Cite this

Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients : Current issues and new agents. / Strasfeld, Lynne; Weinstock, David M.

In: Expert Review of Anti-Infective Therapy, Vol. 4, No. 3, 06.2006, p. 457-468.

Research output: Contribution to journalArticle

@article{538de39383b14632b88a676ea8a5086a,
title = "Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: Current issues and new agents",
abstract = "Invasive candidiasis and invasive mold infections cause significant morbidity and mortality in the hematopoietic stem cell transplant population, in particular in recipients of allografts. The introduction of a variety of new antifungal compounds over the past decade has focused attention on prophylactic strategies as a means to decrease the burden of invasive fungal infections (IFIs). Until recently, fluconazole has been the standard agent for prophylaxis before and after engraftment. In 2005, the echinocandin micafungin received US FDA approval for prophylaxis against IFIs in stem cell transplant recipients during the neutropenic period prior to engraftment. In patients with substantial risk for invasive mold infection, many centers now use a mold-active antifungal agent (e.g., a triazole such as itraconazole, voriconazole or posaconazole, or an echinocandin) as prophylaxis after engraftment. Several recent studies have highlighted the efficacy of these newer agents in preventing IFIs in these highly immunocompromised patients. This review will discuss current issues in IFI and new agents available for prophylaxis in allogeneic hematopoietic stem cell transplant recipients.",
keywords = "Antifungals, Prophylaxis, Stem cell transplant, Voriconazole",
author = "Lynne Strasfeld and Weinstock, {David M.}",
year = "2006",
month = "6",
doi = "10.1586/14787210.4.3.457",
language = "English (US)",
volume = "4",
pages = "457--468",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients

T2 - Current issues and new agents

AU - Strasfeld, Lynne

AU - Weinstock, David M.

PY - 2006/6

Y1 - 2006/6

N2 - Invasive candidiasis and invasive mold infections cause significant morbidity and mortality in the hematopoietic stem cell transplant population, in particular in recipients of allografts. The introduction of a variety of new antifungal compounds over the past decade has focused attention on prophylactic strategies as a means to decrease the burden of invasive fungal infections (IFIs). Until recently, fluconazole has been the standard agent for prophylaxis before and after engraftment. In 2005, the echinocandin micafungin received US FDA approval for prophylaxis against IFIs in stem cell transplant recipients during the neutropenic period prior to engraftment. In patients with substantial risk for invasive mold infection, many centers now use a mold-active antifungal agent (e.g., a triazole such as itraconazole, voriconazole or posaconazole, or an echinocandin) as prophylaxis after engraftment. Several recent studies have highlighted the efficacy of these newer agents in preventing IFIs in these highly immunocompromised patients. This review will discuss current issues in IFI and new agents available for prophylaxis in allogeneic hematopoietic stem cell transplant recipients.

AB - Invasive candidiasis and invasive mold infections cause significant morbidity and mortality in the hematopoietic stem cell transplant population, in particular in recipients of allografts. The introduction of a variety of new antifungal compounds over the past decade has focused attention on prophylactic strategies as a means to decrease the burden of invasive fungal infections (IFIs). Until recently, fluconazole has been the standard agent for prophylaxis before and after engraftment. In 2005, the echinocandin micafungin received US FDA approval for prophylaxis against IFIs in stem cell transplant recipients during the neutropenic period prior to engraftment. In patients with substantial risk for invasive mold infection, many centers now use a mold-active antifungal agent (e.g., a triazole such as itraconazole, voriconazole or posaconazole, or an echinocandin) as prophylaxis after engraftment. Several recent studies have highlighted the efficacy of these newer agents in preventing IFIs in these highly immunocompromised patients. This review will discuss current issues in IFI and new agents available for prophylaxis in allogeneic hematopoietic stem cell transplant recipients.

KW - Antifungals

KW - Prophylaxis

KW - Stem cell transplant

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=33745225428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745225428&partnerID=8YFLogxK

U2 - 10.1586/14787210.4.3.457

DO - 10.1586/14787210.4.3.457

M3 - Article

C2 - 16771622

AN - SCOPUS:33745225428

VL - 4

SP - 457

EP - 468

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 3

ER -